SCHEMBL10006709

SCHEMBL10006709

CCOC(=O)c1cnc(Cc2cccc(Cl)c2)nc1NC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.53
▸ ALDH1A1 P00352 4/20 0.53
▸ HSD17B10 Q99714 3/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ FOS P01100 1/20 0.53
▸ JUN P05412 1/20 0.53
▸ NFKB1 P19838 1/20 0.53
▸ NFKB2 Q00653 1/20 0.53
▸ RELA Q04206 1/20 0.53
▸ KMT2A Q03164 4/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ PDE3B Q13370 1/20 0.51
▸ PDE3A Q14432 1/20 0.51
▸ MAOB P27338 2/20 0.48
▸ MAPK1 P28482 3/20 0.47
▸ LMNA P02545 4/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ HTT P42858 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10006645 0.85 LMNA (0.45) MAPTKMT2ALMNAMEN1SIRT5
SCHEMBL10260712 0.78 CYP1A2 (0.45) MAPTALDH1A1KDM4EFOSJUN
SCHEMBL8395191 0.77 FOS (0.48) MAPTALDH1A1HSD17B10KDM4ENPC1
SCHEMBL8394439 0.77 NFKB1 (0.65) MAPTALDH1A1HSD17B10KDM4ENPC1
SCHEMBL1301085 0.77 GABRA1 (0.50) MAPTALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL14810384 0.76 KDM4E (0.57) MAPTALDH1A1HSD17B10KDM4ENPC1
SCHEMBL10007036 0.76 PDE3B (0.64) MAPTALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL12929741 0.74 FOS (0.66) MAPTALDH1A1HSD17B10KDM4ENPC1
SCHEMBL12812401 0.73 MAPT (0.60) MAPTALDH1A1NPC1HPGDKMT2A
SCHEMBL1300825 0.73 MAPT (0.55) MAPTALDH1A1KDM4EHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2476682-B1 8-OXODIHYDROPURINE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2017-04-26 — — EP disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 — — US disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 — — US disclosed
US-8735406-B2 8-oxodihydropurine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-05-27 — — US disclosed
EP-2476682-A1 8-OXODIHYDROPURINE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-07-18 — — EP disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 — — US disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 — — US disclosed
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172347-A1 8-OXODIHYDROPURINE DERIVATIVE FAAH, FAAH2, TPMT MAPT 2670/4885ALDH1A1 50/4885HSD17B10 1128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback